Miniaturized catheter designed to treat pulmonary disease

 

SAUSALITO, Calif. ─ January 17, 2013, ─ Sanovas Inc., a life science technology
company developing and commercializing the next-generation of micro-invasive
diagnostics, devices, and drug delivery technologies, announced today that it has
filed with the U.S. Food and Drug Administration for clearance of the company’s Vas
Zeppelin™ Smart Catheter™ for the treatment of chronic pulmonary diseases and
lung cancer. The technology would be among the smallest interventional catheters
commercially available, allowing physicians to access and deliver therapy to some of
the tiniest and most remote passageways in the anatomy.

“This filing marks a significant milestone for Sanovas and beacons new opportunity for
physicians and patients alike,” Sanovas CEO Larry Gerrans said. “With one in seven
Americans suffering from chronic pulmonary disease and with lung cancer killing more
people than breast, prostate and colon cancers combined, new technologies aimed at
the earliest stages of lung disease are desperately needed.”

Worldwide, hundreds of millions of people suffer every day from chronic respiratory
diseases. According to the World Health Organization, 235 million people suffer from
asthma and 64 million suffer from chronic obstructive pulmonary disease.  While Lung
cancer alone kills over one million people every year.

Existing surgical tools and technologies have long been recognized as being too
invasive and/or too risky to be implemented in standard clinical practice because of the
potential damage to the treatment site and/or post-operative complications. Sanovas is
developing a system of miniaturized technologies intended to overcome the complexity
and procedural risks associated with a pulmonary intervention.

The Vas Zeppelin™ Smart Catheter System™ is being designed to provide surgeons
the first intelligent, integrated approach to operating on a breathing lung. The system
will feature a portfolio of integrated tools and sensors. The solution set is intended to
synergize access, 3D imaging, physiologic metrics, onboard diagnostics and related

therapy- enabling technologies to remove obstructions and to deliver drug and immune
therapies to targeted locations.

The Vas Zeppelin™ is the first component of the Vas Zeppelin™ Smart Catheter
System™. It is intended to offer an immediate, meaningful solution to physicians and
patients and to serve as the cornerstone to the company’s arsenal of therapy enabling
solutions. With two patents issued and more than 40 patents pending, Sanovas’ strong
intellectual property portfolio offers broad protection of the Vas Zeppelin™ Smart
Catheter System™. The company will be actively filing for clearance of its follow-on
technologies over the ensuing months.

About Sanovas

Sanovas, Inc., based in Sausalito, Calif., is a life science technology company
developing and commercializing next generation micro-invasive diagnostics, devices
, and drug delivery technologies for unmet clinical needs. Sanovas' microsurgical
technology platform is designed to give surgeons the ability to access and visualize
previously inaccessible areas of the body; enabling them to diagnose, treat and deliver
drug and immune therapies to small diameter anatomy in entirely new ways. Privately
held, Sanovas was founded by pioneers in minimally invasive surgery. The company
has two patents issued and more than 40 multi-national patents pending.

Media Contact:

Steve Goldsmith
VP Marketing, Sanovas
415 729 9391 ext. 1023
This email address is being protected from spambots. You need JavaScript enabled to view it.

FDA REGULATORY DISCLOSURE: Sanovas Inc. is an emerging technology company.
These products are investigational medical devices that have not been approved or cleared for use in the United States.